scholarly journals Stable expression of Mycobacterium bovis antigen 85B in auxotrophic M. bovis bacillus Calmette-Guérin

2017 ◽  
Vol 112 (2) ◽  
pp. 123-130 ◽  
Author(s):  
Caroline Rizzi ◽  
◽  
Ana Carolina Peiter ◽  
Thaís Larré Oliveira ◽  
Amilton Clair Pinto Seixas Neto ◽  
...  
2018 ◽  
Vol 86 (8) ◽  
Author(s):  
Naoto Noguchi ◽  
Risa Nakamura ◽  
Shinya Hatano ◽  
Hisakata Yamada ◽  
Xun Sun ◽  
...  

ABSTRACT Interleukin 21 (IL-21) is a pleiotropic common cytokine receptor γ chain cytokine that promotes the effector functions of NK cells and CD8+ T cells and inhibits CD8+ T cell exhaustion during chronic infection. We found that the absolute number of short-lived effector CD8+ T cells (SLECs) (KLRG1high CD127low) decreased significantly in IL-21 receptor-deficient (IL-21R−/−) mice during Mycobacterium bovis bacillus Calmette-Guérin (BCG) infection. Early effector CD8+ T cells (EECs) (KLRG1low CD127low) were normally generated in IL-21R−/− mice after infection. Exhausted CD8+ T cells (PD-1high KLRG1low) were also normally generated in IL-21R−/− mice after infection. Mixed bone marrow (BM) chimera and transfer experiments showed that IL-21R on CD8+ T cells was essential for the proliferation of EECs, allowing them to differentiate into SLECs after BCG infection. On the other hand, the number of SLECs increased significantly after infection with recombinant BCG (rBCG) that secreted an antigen 85B (Ag85B)–IL-21 fusion protein (rBCG–Ag85B–IL-21), but the number of exhausted CD8+ T cells did not change after rBCG–Ag85B–IL-21 infection. These results suggest that IL-21 signaling drives the differentiation of SLECs from EECs but does not inhibit the exhaustion of CD8+ T cells following BCG infection in mice.


2011 ◽  
Vol 141 (2) ◽  
pp. 642-652.e4 ◽  
Author(s):  
Micheline Lagranderie ◽  
Christoph Kluge ◽  
Helene Kiefer–Biasizzo ◽  
Mohammad Abolhassani ◽  
Marie–Anne Nahori ◽  
...  

Vaccine ◽  
2014 ◽  
Vol 32 (45) ◽  
pp. 5998-6004 ◽  
Author(s):  
Richard Copin ◽  
Mireia Coscollá ◽  
Efstratios Efstathiadis ◽  
Sebastien Gagneux ◽  
Joel D. Ernst

npj Vaccines ◽  
2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Junli Li ◽  
Lingjun Zhan ◽  
Chuan Qin

AbstractBacillus Calmette–Guérin (BCG), the only vaccine proven to be effective against tuberculosis (TB), is the most commonly used vaccine globally. In addition to its effects on mycobacterial diseases, an increasing amount of epidemiological and experimental evidence accumulated since its introduction in 1921 has shown that BCG also exerts non-specific effects against a number of diseases, such as non-mycobacterial infections, allergies and certain malignancies. Recent Corona Virus Disease 2019 (COVID-19) outbreak has put BCG, a classic vaccine with significant non-specific protection, into the spotlight again. This literature review briefly covers the diverse facets of BCG vaccine, providing new perspectives in terms of specific and non-specific protection mechanisms of this old, multifaceted, and controversial vaccine.


PLoS ONE ◽  
2014 ◽  
Vol 9 (5) ◽  
pp. e97031 ◽  
Author(s):  
Mitchell V. Palmer ◽  
Tyler C. Thacker ◽  
W. Ray Waters ◽  
Suelee Robbe-Austerman

2020 ◽  
Vol 100 ◽  
pp. 373-376 ◽  
Author(s):  
Mihoko Furuichi ◽  
Fumi Mori ◽  
Yoji Uejima ◽  
Satoshi Sato ◽  
Jun Kurihara ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document